Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
IPO Year: 2001
Exchange: NASDAQ
Website: exactsciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $60.00 | Outperform | Mizuho |
| 3/13/2025 | $52.00 | Sector Perform | RBC Capital Mkts |
| 1/23/2025 | $70.00 | Overweight | Barclays |
| 8/28/2024 | $75.00 | Overweight | Wells Fargo |
| 6/27/2024 | $70.00 | Sector Outperform | Scotiabank |
| 6/3/2024 | $75.00 | Buy | Jefferies |
| 1/2/2024 | $91.00 | Hold → Buy | The Benchmark Company |
| 12/14/2023 | $90.00 | Buy | Guggenheim |
| 12/13/2023 | $95.00 | Outperform | Wolfe Research |
| 10/10/2023 | $90.00 | Neutral → Overweight | Piper Sandler |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
10-Q - EXACT SCIENCES CORP (0001124140) (Filer)
8-K - EXACT SCIENCES CORP (0001124140) (Filer)
S-8 POS - EXACT SCIENCES CORP (0001124140) (Filer)
S-8 - EXACT SCIENCES CORP (0001124140) (Filer)
11-K - EXACT SCIENCES CORP (0001124140) (Filer)
8-K - EXACT SCIENCES CORP (0001124140) (Filer)
SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
10-Q - EXACT SCIENCES CORP (0001124140) (Filer)
8-K - EXACT SCIENCES CORP (0001124140) (Filer)
DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00
RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00
Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00
Wells Fargo initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $75.00
Scotiabank initiated coverage of Exact Sciences with a rating of Sector Outperform and set a new price target of $70.00
Jefferies resumed coverage of Exact Sciences with a rating of Buy and set a new price target of $75.00
The Benchmark Company upgraded Exact Sciences from Hold to Buy and set a new price target of $91.00
Guggenheim initiated coverage of Exact Sciences with a rating of Buy and set a new price target of $90.00
Wolfe Research initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $95.00
Piper Sandler upgraded Exact Sciences from Neutral to Overweight and set a new price target of $90.00
Fastest customizable press release news feed in the world
Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect™ molecular residual disease and recurrence monitoring test Announced a multi-year productivity p
Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences' leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current an
Cologuard Plus™ Available In-Network August 2025 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August 2025. Humana, the fourth largest private insurer in the United States, has approximately 5.8 million Medicare Advantage members. "The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, d
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period. The final LCD can be found here, and the billing and coding article here, from CMS. This marks a significant milestone in the company's mission to transform cancer treatment through earlier detection and more personalize
Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer Whole-genome Oncodetect test powered by MAESTRO to launch in 2026 with ultra-low limit of detection1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) t
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success o
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard® test that underscore Exact Sciences' expanding portfolio and commitment to advancing care through scientific excellence. "The data Exact Sciences will present at ASCO 2025 reflect the scientific rigor and clinical significance of o
Award marks seventh consecutive year company has received prestigious distinction Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and leadership. This year, 77% of employees called Exact Sciences a Great Place To Work – 20 points higher than the average U.S.-based company. Great Place
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the suc
This live feed shows all institutional transactions in real time.
SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
Live finance-specific insights
Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect™ molecular residual disease and recurrence monitoring test Announced a multi-year productivity p
Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences' leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current an
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, d
First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod
Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date: Wednesday, February 19, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers
Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14% Operating cash flow was $139 million with free cash flow of $113 million Received FDA approval for the Cologuard Plus™ test, the Company's next-generation Cologuard® test Presented data showing potential of its blood-based colorectal cancer screening test, with sens
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2024 webcast & conference call details Date: Tuesday, November 5, 2024 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 Inte
Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million Screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX® Advanced pipeline by generating evidence supporting molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests Maintains full-year 2024 revenue guidance and
Live Leadership Updates
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same
CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial results, drove operational rigor, led strategic growth initiatives, played key roles in portfolio management, acquisitions, and divestitures, and set corporate strategy and vision. At Baxter, Mr. Bloomer led corporate financial planning, reporting, and analytics (FP&A) as vice president. Prior to t
In collaboration with The Blue Hat Foundation, "Box Out Colon Cancer" offers a timely spotlight on screening and prevention for the nation's #2 cancer-related killer1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, genders, and ethnicities – in line with American Cancer Society reco
Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5-$647.5 million, an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0-$487.0 million and Precision Oncology revenue of $159.5-$160.5 millionExpects total full-year 2023 revenue of $2.50 billion and 2024 revenue of $2.83 billionSubmitted final module of next-generation Cologuard premarket approval application to FDAAnnounces Jeff Elliott plans to step down as Executive Vice President and Chief Financia
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t
FORT MILL, S.C., March 01, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Katherine S. Zanotti to the company's board of directors, effective March 1, 2022. This appointment will bring the total number of directors to eleven. "We are delighted to welcome Katherine (‘Kay') to our board. Kay's long history of leadership coupled with her extensive experience in sales and marketing within the foodservice and health care sectors makes her a great addition and helps position Diversey for continued growth and success," said Phil Wieland, CEO of Diversey. Katherine S. Zanotti served as
Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006301/en/Sam Asgarian, M.D., MBA, Scipher Medicine, Chief Medical Officer (Photo: Business Wire) "We are thrilled to welcome Dr. Asgarian to our leadership team," said Alif Saleh, chief executive officer of Scipher Medicine. "His strong blend of experience as a health care clinician and business leader will serve us well as we pursue our critical mission." Dr. Asgarian joins Sci